Bergamaschi, Roberto, Marco Capobianco, and Roberto Ravasio. “Budget Impact Analysis of Natalizumab Biosimilar on Pharmaceutical Expenditure for the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy”. AboutOpen 11, no. 1 (June 17, 2024): 48–56. Accessed December 4, 2024. https://journals.aboutscience.eu/index.php/aboutopen/article/view/3078.